Markets

Aimmune Therapeutics (AIMT) in Focus: Stock Moves 6.3% Higher

Aimmune Therapeutics, Inc.AIMT was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company-as the stock is now up 25.2% in the past one-month time frame.

The company has seen no estimate revisions over the past few weeks, while the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Aimmune Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Aimmune Therapeutics, Inc. Price

Aimmune Therapeutics, Inc. Price | Aimmune Therapeutics, Inc. Quote

A better-ranked stock in the Medical - Biomedical and Genetics industry is Ligand Pharmaceuticals Incorporated LGND , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Is AIMT going up? Or down? Predict to see what others think: Up or Down

Can Hackers Put Money INTO Your Portfolio?

Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.

Zacks has just released Cybersecurity! An Investor's Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.

Download the new report now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report

Aimmune Therapeutics, Inc. (AIMT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AIMT LGND

Other Topics

Investing Stocks